Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Currently, fluorine-18 labeled fluorodeoxyglucose (FDG), a glucose analogue, is the most commonly used imaging agent for positron emission tomography (PET) in cancer patients. The excellent clinical information obtained by the FDG PET has made it essential in the management of many cancers. Despite its proven clinical utilities, FDG PET has some well known limitations. Several other agents for PET imaging have been developed, which can overcome certain limitations of FDG, provide new information on the biologic, metabolic and molecular characteristics of malignant tumors, and aid in the diagnosis, optimal therapeutic approach, prognostic assessment and therapy monitoring in cancer patients. This review focuses on the biological basis of cancer imaging with some PET imaging agents, other than FDG, and their potential clinical applications. Emphasis is given to 1) choline, a precursor of cell membrane phospholipids, 2) acetate, an intermediate of lipid metabolism, 3) methionine, an essential amino acid, 4) fluorothymidine, a nucleoside analog and marker of cellular proliferation, and 5) fluoromisonidazole, a nitroimidazole derivative and marker of hypoxia.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: August 1, 2007
More about this publication?
- Current Medical Imaging Reviews publishes frontier reviews on all the latest advances on medical imaging. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques.
The journal's aim is to publish the highest quality review articles dedicated to research in the field. The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites